FDA will delay Moderna shot for adolescents as it studies potential adverse heart reaction

Nordic countries have already issued directives to withhold specific vax from younger patients.

Published: October 16, 2021 8:48am

Updated: October 16, 2021 8:49am

The U.S. Food and Drug Administration this week announced that it would delay the authorization of Moderna’s COVID-19 vaccine for adolescents while it studies reports of an adverse heart reaction to the drug in younger patients.

Sources told the Wall Street Journal that “the FDA has been taking another look at the risk of the condition, known as myocarditis, among younger men who took Moderna’s vaccine,” especially compared to those who received other brands of the vaccine.”

The investigation comes shortly after the Nordic countries announced their own restrictions on administering the vaccination to younger patients, citing the potential risk of myocarditis. 

The FDA’s delay here “could be several weeks, but the timing is unclear,” the Journal reported.

Unlock unlimited access

  • No Ads Within Stories
  • No Autoplay Videos
  • VIP access to exclusive Just the News newsmaker events hosted by John Solomon and his team.
  • Support the investigative reporting and honest news presentation you've come to enjoy from Just the News.
  • Just the News Spotlight

    Support Just the News